Empirical antifungal therapy in selected patients with persistent fever and neutropenia

被引：9

作者：

Cisneros, JM

Espigado, I

Rivero, A

de León, FL

Parra, J

Collado, AR

Lomas, JM

Pachón, J

机构：

[1] Hosp Univ Virgen Rocio, Unidad Gest Clin Enfermedades Infecciosas, Seville 41013, Spain

[2] Hosp Univ Virgen Rocio, Serv Hematol, Seville, Spain

[3] Hosp Univ Reina Sofia, Unidad Enfermedades Infecciosas, Cordoba, Spain

[4] Hosp Univ Virgen Valme, Unidad Enfermedades Infecciosas, Seville, Spain

[5] Hosp Clin San Cecilio, Unidad Enfermedades Infecciosas, Granada, Spain

[6] Hosp Torrecardenas, Unidad Enfermedades Infecciosas, Almeria, Spain

[7] Hosp Juan Ramon Jimenez, Med Interna Serv, Huelva, Spain

来源：

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2005年 / 23卷 / 10期

关键词：

antifungal; antifungal therapy; empirical therapy; neutropenia;

D O I：

10.1016/S0213-005X(05)75041-2

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Empirical antifungal treatment (EAT) in neutropenia is mainly aimed at improving the poor prognosis of patients with invasive fungal infection through early treatment. The Infectious Diseases Society of America recommends initiating EAT in patients with persistent fever after 5-7 days of antibacterial treatment, and in those in whom remission of neutropenia is not imminent. Nevertheless, EAT has not been shown to be more effective than a placebo, it does not show better results than directed antifungal treatment, its effectiveness is minimal, it is not innocuous, and it is not very efficient with the use of most antifungal agents. All considered, we believe that the aforementioned recommendation for EAT treatment is unjustified. In its place we propose the application of EAT in patients selected on the basis of clinical criteria and risk factors.

引用

页码：609 / 614

页数：6

共 38 条

[1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[2] Numbers needed to treat (needlessly?) [J].

Bogaty, P ;

Brophy, J .

LANCET, 2005, 365 (9467) :1307-1308

[3] Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy - A randomized, controlled trial [J].

Boogaerts, M ;

Winston, DJ ;

Bow, EJ ;

Garber, G ;

Reboli, AC ;

Schwarer, AP ;

Novitzky, N ;

Boehme, A ;

Chwetzoff, E ;

De Beule, K .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) :412-422

[4] Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [J].

Dellinger, RP ;

Carlet, JM ;

Masur, H ;

Gerlach, H ;

Calandra, T ;

Cohen, J ;

Gea-Banacloche, J ;

Keh, D ;

Marshall, JC ;

Parker, MM ;

Ramsay, G ;

Zimmerman, JL ;

Vincent, JL ;

Levy, MM .

CRITICAL CARE MEDICINE, 2004, 32 (03) :858-873

[5] Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial [J].

Eriksson, U ;

Seifert, B ;

Schaffner, A .

BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7286) :579-582

[6] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].

GOODMAN, JL ;

WINSTON, DJ ;

GREENFIELD, RA ;

CHANDRASEKAR, PH ;

FOX, B ;

KAIZER, H ;

SHADDUCK, RK ;

SHEA, TC ;

STIFF, P ;

FRIEDMAN, DJ ;

POWDERLY, WG ;

SILBER, JL ;

HOROWITZ, H ;

LICHTIN, A ;

WOLFF, SN ;

MANGAN, KF ;

SILVER, SM ;

WEISDORF, D ;

HO, WG ;

GILBERT, G ;

BUELL, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851

[7] BRAIN-ABSCESS FOLLOWING MARROW TRANSPLANTATION - EXPERIENCE AT THE FRED-HUTCHINSON-CANCER-RESEARCH-CENTER, 1984-1992 [J].

HAGENSEE, ME ;

BAUWENS, JE ;

KJOS, B ;

BOWDEN, RA .

CLINICAL INFECTIOUS DISEASES, 1994, 19 (03) :402-408

[8] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[9] Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed tomography [J].

Heussel, CP ;

Kauczor, HU ;

Heussel, GE ;

Fischer, B ;

Begrich, M ;

Mildenberger, P ;

Thelen, M .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :796-805

[10] 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].

Hughes, WT ;

Armstrong, D ;

Bodey, GP ;

Bow, EJ ;

Brown, AE ;

Calandra, T ;

Feld, R ;

Pizzo, PA ;

Rolston, KVI ;

Shenep, JL ;

Young, LS .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751

← 1 2 3 4 →